导师信息#中国药科大学中药学院研究生导师介绍#寇俊萍

liyuanhua

一般情况
寇俊萍，女，博士，中西医结合基础（药学），教授，博士生导师,中国药科大学中药学院副院长，中药复方研究室主任。国家自然科学基金医学部中医中药学科同行评议专家，教育部科技成果与奖励评审专家，江苏省青蓝工程优秀青年骨干教师，教育部新世纪优秀人才。世界中医药联合会中医药免疫专业委员会常务理事，中华中医药学会中药实验药理分会常务委员，中国药理学会网络药理专业委员会委员，江苏省药理学会理事，中国实验方剂学杂志/中国药科大学学报编委。
联系方式咨询QQ、微信：2544906的功能靶标发现和相关信号转导通路研究(教育部新世纪优秀人才支持计划,NCET-07-0849,25万)[4]从1型组胺受体途径探索当归芍药散异病同治原理研究(国家自然科学基金30873322,31万)[5]基于NMMHCⅡA-TF信号通路探讨麦冬皂苷防治血栓性疾病的新机制研究（国家自然科学基金面上项目，81274131,70万）[6]基于组织因子及其信号转导途径的异喹啉生物碱类成分的构效关系与作用机理研究(教育部中央高校基本科研业务费专项资金项目,JKZ2009010,15万)[7]基于功能蛋白及信号转导网络探讨生脉散多成分防治脑缺血的整合机制研究（自主科研重点项目，JKZ201107,25万）[8]新型天然抗过敏化合物THBP的分子机制研究（教育部留学回国人员科研启动基金,3万）[9]生脉散有效成分群调控AMPK/NMMHCIIA/14-3-3防治心肌缺血再灌注损伤多靶点整合机制(国家自然科学基金面上项目，81573719,72万)
③所获奖励[1]麦冬类中药的系统研究.教育部高等学校科学研究优秀成果奖（自然科学）二等奖(排名第2),教育部,2011.1[2]江苏省第5届优秀青年中医药（中西医结合）工作者，2010.3[3]江苏省教育科技系统五一巾帼标兵,2013.5
④研究生培养承担两门研究生专业必修课的讲授，《中药现代研究的思路与方法导论》《新概念方剂学导论》,均为江苏省优秀研究生课程；参与博士生课程《天然药物研究方法选论》的授课，至2015年6月，指导及协助指导中西医结合基础和生药学专业研究生61名，已毕业9名博士，31名硕士，8名研究生获江苏省研究生创新计划资助，2名博士生获国家建设高水平大学公派研究生项目资助，分别赴美国耶鲁大学，加拿大曼尼托巴大学交流学习。
⑤主要代表性论文及专利[1]Non-muscle myosin heavy chain IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3β-NF-κB signaling pathways in the endothelium. Thromb Haemostasis. 2015;114(1):173-185.[2]The saponin DT-13 attenuates tumor necrosis factor-a-induced vascular inflammation associated with Src/NF-kB/MAPK pathway modulation. Int J Biol Sci, 2015;11(8):970-981[3]Beneficial effect of Danggui-Shaoyao-San, a traditional Chinese medicine, on drowsiness induced by chronic restraint stress. Neurosci Lett. 2015; 597: 26-31. [4]Cocktail of four active components derived from Sheng-mai San inhibits hydrogen peroxide induced PC12 cell apoptosis linked with caspase-3/ROCK1/MLC pathway. Rejuv Res. 2015 May 18. [Epub ahead of print].[5]Diosgenin regulates adipokine expression in perivascular adipose tissue and ameliorates endothelial dysfunction via regulation of AMPK. J Steroid Biochem Mol Biol. 2015 Aug 12. doi: 10.1016/j.jsbmb.2015.07.005[6]A combination of four active compounds alleviates cerebral ischemia-reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways. J Neurosci Res. 2014;92(10):1295-306.[7]Ruscogenin reduces cerebral ischemic injury via NF-κB-mediated inflammatory pathway in the mouse model of experimental stroke. Eur J Pharmacol. 2013;714(1-3):303-311[8]Diosgenin down-regulates NF-κB p65/p50 and p38MAPK pathways and attenuates acute lung injury induced by lipopolysaccharide in mice. Int Immunopharmacol. 2013,15(2):240-245[9]Chemical and microbial semi-synthesis of tetrahydroprotoberberines as inhibitors on tissue factor procoagulant activity. Bioorg & Med Chem, 2013,21(1):62–69[10]Diosgenin ameliorates palmitate- induced endothelial dysfunction and insulin resistance via blocking IKKb and IRS-1 pathways. Atherosclerosis, 2012,223(2): 350-358[11]Safety evaluation of steroidal saponin DT-13 isolated from the tuber of Liriope muscari (Decne.) Baily. Food Chem Toxicol 2011;49(9):2243-2251[12]Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-kB activation. Neurochem Int 2011, 58(1):119-125[13]Ruscogenin mainly inhibits nuclear factor-κB but not Akt and mitogen-activated protein kinase signaling pathways in human umbilical vein endothelial cells. J Pharmacol Sci 2010,113(4), 409 – 413[14]Hypothesis on the principle of Danggui-Shao yao-San (DSS) for treating different diseases via the histamine H1 Receptor pathway. Modern Tradit Chin Med Mater Med, 2010, 12(3): 325–330[15]The effects of twelve representative flavonoids on tissue factor expression in human monocytes: Structure-activity relationships. Thromb Res. 2009, 124(6): 714–720.[16]Neuroprotective effects of the aqueous extract of Chinese medicine Danggui-Shaoyao -san on aged mice. J Ethnopharmacol. 2005, 97:313-318.[17]Inhibitory effect of ethanol extract from Radix Ophiopogonis japonicus on venous thrombosis linked with its endothelium-protective and anti-adhesive activities. Vasc Pharmacol. 2005,43(3): 157 – 163.[18]寇俊萍，张建宏，朱丹妮，戚 进，余伯阳，严永清．一种防治心脑血管疾病的中药有效部位组合物及制备方法，中国授权专利ZL 200710020901.7[19]寇俊萍，余伯阳，戚进，稻垣直树，朱丹妮。2-O-α-L-鼠李糖-4, 6, 4′-三羟基二苯甲酮的医药用途，中国授权专利：ZL200810244795.5 &ZL 201010143336.5[20]余伯阳, 寇俊萍, 黄娅琳, 蒋文雯, 刘吉华. 一种防治炎症相关心脑血管疾病的药物靶标及其抑制剂，中国授权专利ZL 200710024810.0,